Ypsomed Holding AG
YPSN
Rangering i aksjer
#2948
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and... Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Aksjekurs
$469.39
Markedsverdi
$6.17B
Endring (1 dag)
1.63%
Endring (1 år)
18.98%
Land
CH
Handel Ypsomed Holding AG (YPSN)
Kategori
Healthcare
Inntekter for Ypsomed Holding AG (YPSN)
Inntekter i Oct 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Ypsomed Holding AG er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Ypsomed Holding AG fra 2002 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2025 | $847.04M | 39.34% |
| 2024 | $607.88M | 11.82% |
| 2023 | $543.61M | 7.97% |
| 2022 | $503.49M | 17.75% |
| 2021 | $427.58M | 4.29% |
| 2020 | $409.99M | -10.08% |
| 2019 | $455.95M | -6.76% |
| 2018 | $489.00M | 25.91% |
| 2017 | $388.37M | 10.90% |
| 2016 | $350.19M | 10.82% |
| 2015 | $316.01M | 1.22% |
| 2014 | $312.21M | 21.22% |
| 2013 | $257.56M | -6.31% |
| 2012 | $274.90M | 3.86% |
| 2011 | $264.69M | 9.99% |
| 2010 | $240.64M | 0.57% |
| 2009 | $239.28M | -17.28% |
| 2008 | $289.26M | 26.94% |
| 2007 | $227.87M | -4.32% |
| 2006 | $238.15M | 17.72% |
| 2005 | $202.31M | 38.65% |
| 2004 | $145.92M | 43.99% |
| 2003 | $101.34M | 69.52% |
| 2002 | $59.78M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $6.04B | - |
IE
|
|
| - | - |
CN
|
|
| - | - |
CH
|
|
| - | - |
CN
|
|
| $352.16M | - |
KR
|
